Zimmer Biomet Holdings Inc (ZBH) CEO Acquires $50,442.30 in Stock

Share on StockTwits

Zimmer Biomet Holdings Inc (NYSE:ZBH) CEO Bryan C. Hanson purchased 410 shares of Zimmer Biomet stock in a transaction on Friday, August 31st. The stock was bought at an average price of $123.03 per share, with a total value of $50,442.30. Following the transaction, the chief executive officer now owns 25,487 shares of the company’s stock, valued at $3,135,665.61. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Zimmer Biomet stock opened at $123.70 on Friday. Zimmer Biomet Holdings Inc has a 12 month low of $104.28 and a 12 month high of $129.34. The company has a market cap of $24.93 billion, a P/E ratio of 15.40, a PEG ratio of 2.25 and a beta of 1.09. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.41 and a quick ratio of 1.25.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.99 billion. During the same period in the prior year, the company earned $2.08 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. research analysts predict that Zimmer Biomet Holdings Inc will post 7.67 earnings per share for the current year.

A number of research firms have recently weighed in on ZBH. Raymond James upped their price objective on Zimmer Biomet from $135.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, July 30th. Robert W. Baird upped their price objective on Zimmer Biomet from $121.00 to $132.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Citigroup upped their price objective on Zimmer Biomet from $117.00 to $128.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 31st. Jefferies Financial Group upped their price objective on Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Finally, Piper Jaffray Companies upped their price objective on Zimmer Biomet from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the company. Zimmer Biomet has an average rating of “Buy” and an average target price of $135.10.

A number of institutional investors have recently made changes to their positions in ZBH. MainStreet Investment Advisors LLC lifted its stake in shares of Zimmer Biomet by 8.9% in the 2nd quarter. MainStreet Investment Advisors LLC now owns 4,881 shares of the medical equipment provider’s stock valued at $544,000 after purchasing an additional 399 shares during the last quarter. Bradley Foster & Sargent Inc. CT lifted its stake in shares of Zimmer Biomet by 6.7% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 6,773 shares of the medical equipment provider’s stock valued at $755,000 after purchasing an additional 423 shares during the last quarter. TD Asset Management Inc. lifted its stake in shares of Zimmer Biomet by 0.7% in the 2nd quarter. TD Asset Management Inc. now owns 61,859 shares of the medical equipment provider’s stock valued at $6,894,000 after purchasing an additional 425 shares during the last quarter. MUFG Americas Holdings Corp lifted its stake in shares of Zimmer Biomet by 18.0% in the 2nd quarter. MUFG Americas Holdings Corp now owns 2,906 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 443 shares during the last quarter. Finally, UMB Bank N A MO lifted its stake in shares of Zimmer Biomet by 4.5% in the 2nd quarter. UMB Bank N A MO now owns 10,467 shares of the medical equipment provider’s stock valued at $1,167,000 after purchasing an additional 455 shares during the last quarter. 87.19% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: What does EPS mean?

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply